Free Trial
Marc Frahm

Marc Frahm Analyst Performance

Biotechnology Equity Research Analyst at TD Cowen

Marc Frahm is a stock analyst at TD Cowen in the medical sector, covering 8 publicly traded companies. Over the past year, Marc Frahm has issued 3 stock ratings, including buy and hold recommendations. While full access to Marc Frahm's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Marc Frahm's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
40 Last 7 Years
Buy Recommendations
92.50% 37 Buy Ratings
Companies Covered
8 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy92.5%37 ratings
Hold7.5%3 ratings
Sell0.0%0 ratings

Out of 40 total stock ratings issued by Marc Frahm at TD Cowen, the majority (92.5%) have been Buy recommendations, followed by 7.5% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
8 companies

Marc Frahm, an analyst at TD Cowen, currently covers 8 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
8 companies
100.0%

Marc Frahm of TD Cowen specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
5 companies
62.5%
MED - DRUGS
2 companies
25.0%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company
12.5%

About Marc Frahm

Prior to joining TD Cowen in July 2013, Marc Frahm was a graduate research assistant at Duke University. At Duke, he studied the T-cell response to HIV, the regulation of PD-L1 expression, and developed an in vitro diagnostic method for the differentiation of active and latent TB infections. Dr. Frahm received a BS in biochemistry from the University of Wisconsin-Madison and his Ph.D. in molecular genetics and microbiology from Duke University.
Follow on LinkedIn

Marc Frahm's Ratings History at TD Cowen

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
3/23/2026Boost Price Target$14.65$15.00Hold
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
3/17/2026Initiated Coverage$72.21Buy
Incyte Corporation stock logo
INCY
Incyte
1/13/2026Boost Price Target$104.89$128.00Buy